New weekly shot could help control blood sugar in type 2 diabetes
NCT ID NCT07163624
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new once-weekly injection called UBT251 in 211 adults with type 2 diabetes. Participants received either UBT251, a placebo, or the existing drug semaglutide for 24 weeks. The main goal was to see how well UBT251 lowers blood sugar (HbA1c) and to find the right dose for future larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UBT251 injection (a once-weekly drug for type 2 diabetes)
What this could lead to
If successful, this could provide a new once-weekly treatment option for people with type 2 diabetes, potentially improving blood sugar control.
What could go wrong
This is a Phase 2 trial with only 211 participants, so results may not apply to everyone. The drug may not work better than existing treatments like semaglutide, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The United Bio-Technology (Hengqin) Co., Ltd.
Zhuhai, Guangdong, 519000, China